English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
  Automatic detection of preclinical neurodegeneration: Presymptomatic Huntington disease

Klöppel, S., Chu, C., Tan, G., Draganski, B., Johnson, H., Paulsen, J., et al. (2009). Automatic detection of preclinical neurodegeneration: Presymptomatic Huntington disease. Neurology, 72(5), 426-431. doi:10.1212/01.wnl.0000341768.28646.b6.

Item is

Files

show Files

Locators

show
hide
Locator:
http://n.neurology.org/content/72/5/426 (Publisher version)
Description:
-
OA-Status:
Not specified

Creators

show
hide
 Creators:
Klöppel, S, Author
Chu, C, Author
Tan, GC, Author
Draganski, B, Author
Johnson, H, Author
Paulsen, JS, Author
Kienzle, W1, 2, Author           
Tabrizi , SJ, Author
Ashburner, J, Author
Frackowiak, RSJ, Author
Affiliations:
1Department Empirical Inference, Max Planck Institute for Biological Cybernetics, Max Planck Society, ou_1497795              
2Max Planck Institute for Biological Cybernetics, Max Planck Society, Spemannstrasse 38, 72076 Tübingen, DE, ou_1497794              

Content

show
hide
Free keywords: -
 Abstract: Background: Treatment of neurodegenerative diseases is likely to be most beneficial in the very early, possibly preclinical stages of degeneration. We explored the usefulness of fully automatic structural MRI classification methods for detecting subtle degenerative change. The availability of a definitive genetic test for Huntington disease (HD) provides an excellent metric for judging the performance of such methods in gene mutation carriers who are free of symptoms.

Methods: Using the gray matter segment of MRI scans, this study explored the usefulness of a multivariate support vector machine to automatically identify presymptomatic HD gene mutation carriers (PSCs) in the absence of any a priori information. A multicenter data set of 96 PSCs and 95 age- and sex-matched controls was studied. The PSC group was subclassified into three groups based on time from predicted clinical onset, an estimate that is a function of DNA mutation size and age.

Results: Subjects with at least a 33 chance of developing unequivocal signs of HD in 5 years were correctly assigned to the PSC group 69 of the time. Accuracy improved to 83 when regions affected by the disease were selected a priori for analysis. Performance was at chance when the probability of developing symptoms in 5 years was less than 10.

Conclusions: Presymptomatic Huntington disease gene mutation carriers close to estimated diagnostic onset were successfully separated from controls on the basis of single anatomic scans, without additional a priori information. Prior information is required to allow separation when degenerative changes are either subtle or variable.

Details

show
hide
Language(s):
 Dates: 2009-02
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: BibTex Citekey: 5891
DOI: 10.1212/01.wnl.0000341768.28646.b6
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Neurology
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 72 (5) Sequence Number: - Start / End Page: 426 - 431 Identifier: -